Ironwood Pharmaceuticals Inc

IRWD remains in a Stage 2 advancing context with price consolidating near the rising 200-day SMA. Medium-term bias stays bullish, but short-term momentum is negative as price trades below the 9/20-day EMA cluster. Execution is deferred: stalk long on pullbacks into the 9/20 EMA zone (~4.15–4.18) or holds at the 200-day SMA (~3.95). The long-term uptrend on the rising 200-day SMA remains intact; a sustained break below that level would invalidate the bullish view.

• ↑Q2 revenue $113M up 33% YoY, driven by Linzess’s 14% sales jump to $282.3M.
• ↑Full-year Linzess net sales guidance raised to $1.15–$1.20B on mid-single-digit demand growth.
• ↓Revenue tied almost exclusively to Linzess, exposing cash flow to demand swings.